Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT1ERKL)

• DTT Name: CD40 messenger RNA (CD40 mRNA)
• Synonyms: Tumor necrosis factor receptor superfamily member 5 (mRNA); TNFRSF5 (mRNA); CDw40 (mRNA); CD40L receptor (mRNA); Bp50 (mRNA); B-cell surfaceantigen CD40 (mRNA); B-cell surface antigen CD40 (mRNA)
• Gene Name: CD40
• DTT Type: Clinical trial target; [1]
• BioChemical Class: mRNA target
• UniProt ID: TNR5_HUMAN
• TTD ID: T50445
• Sequence:
  MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECL
  PCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCV
  LHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTN
  KTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNKAPHPKQEPQEINFPD
  DLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ
• Function: Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion. Receptor for TNFSF5/CD40LG.
• KEGG Pathway:
  Cytokine-cytokine receptor interaction (hsa04060)
  NF-kappa B signaling pathway (hsa04064)
  Cell adhesion molecules (CAMs) (hsa04514)
  Toll-like receptor signaling pathway (hsa04620)
  Intestinal immune network for IgA production (hsa04672)
  Malaria (hsa05144)
  Toxoplasmosis (hsa05145)
  HTLV-I infection (hsa05166)
  Epstein-Barr virus infection (hsa05169)
  Transcriptional misregulation in cancer (hsa05202)
  Asthma (hsa05310)
  Autoimmune thyroid disease (hsa05320)
  Systemic lupus erythematosus (hsa05322)
  Allograft rejection (hsa05330)
  Primary immunodeficiency (hsa05340)
  Viral myocarditis (hsa05416)
• Reactome Pathway:
  TNFR2 non-canonical NF-kB pathway (R-HSA-5668541)
  TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway (R-HSA-5676594)
  Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-HSA-198933)

Molecular Interaction Atlas (MIA) of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NJA-730	DM4I02O	Graft-versus-host disease	4B24	Phase 1	[2]

8 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS 19211	DMKFCD5	Discovery agent	N.A.	Investigative	[1]
ISIS 19212	DMLQT5F	Discovery agent	N.A.	Investigative	[1]
ISIS 19213	DMD1JVZ	Discovery agent	N.A.	Investigative	[1]
ISIS 19217	DMQK0AL	Discovery agent	N.A.	Investigative	[1]
ISIS 19218	DMX4I5A	Discovery agent	N.A.	Investigative	[1]
ISIS 19219	DMFAWGX	Discovery agent	N.A.	Investigative	[1]
ISIS 19220	DMIKEXD	Discovery agent	N.A.	Investigative	[1]
ISIS 19221	DMKOFNX	Discovery agent	N.A.	Investigative	[1]

References

• [1] US patent application no. 6,197,584, Antisense modulation of CD40 expression.
• [2] Clinical pipeline report, company report or official report of NapaJen Pharma.